The vaccine against skin cancer is effective in testing

Researchers say two small-scale skin cancer vaccines that have been tested have proven safe and provide an immune response to cancer cells.

The test results were published in the July 5 issue of Nature.

According to research co-author Patrick Ott of Dana-Farber Cancer Institute in the US city of Boston, in the first study, the vaccine called NeoVax resulted in feasible, safe and potentially free reactions. translation in all patients who receive this vaccine.

In Phase 1 testing of vaccine safety, researchers have vaccinated more than 6 people who treated skin cancer. In the next 25 months, an average of 4 patients did not have metastatic cancer cells. Typically, at least 50% of skin cancer patients recur in 2 years.

Vaccine called NeoVax gives feasible results after testing.

Unlike traditional vaccines to prevent disease, NeoVax aims to prevent 're-emerging' cancer cells in patients with malignant skin cancer after surgery to remove the tumor. However, the team has not been able to conclude this effect of NeoVax temporarily due to the narrow scale of the trial.

In the second study, a team of researchers conducted another vaccine in 13 patients with skin cancer and also had similar conclusions about safety as well as the ability to create an immune response.

These are initial human trials with two types of cancer vaccines from new cancer antigen (neoantigen) , which appear due to mutations in the DNA of cancer cells.

These new antigens do not appear in normal cells of the human body, so this is an ideal target for cancer treatment. Conventional treatments such as chemotherapy destroy both healthy cells and cancer cells, while leaving serious side effects for patients.

Professor Cornelis Melief of the University of Leiden Medical Center in the Netherlands evaluated these two studies to confirm the potential of the treatment. However, he said, it is necessary to conduct trials in the next phase in more groups to see the effectiveness of these vaccines.